Company intelligence
Research Lambda
AI-powered clinical intelligence, RWE and custom built research for pharma and biotech teams
About Research Lambda
Research Lambda is a clinical trial intelligence company helping pharma, biotech, and health systems move from protocol to study startup faster — without the manual bottlenecks that have defined the industry for decades. Our platform applies AI to the hardest problems in clinical operations: protocol feasibility, site and PI identification, and study activation. Where traditional approaches rely on spreadsheets, institutional memory, and months of back-and-forth, Research Lambda delivers data-driven decisions in days. Behind the platform is a team of PhD data scientists and engineers with deep roots in healthcare AI — and a track record that includes research programs for DARPA and ARPA-H. We don't just apply models to clinical data; we understand the biology, the regulatory context, and the operational realities that make healthcare AI uniquely hard to get right. For organizations with problems that go beyond off-the-shelf tools, we also take on custom research engagements: real-world evidence analysis, clinical NLP, knowledge graph construction, and end-to-end AI system development built to government-grade rigor. Research Lambda is operated by Health Innovations Operating Company, LLC, a Delaware limited liability company. Clinical research moves too slowly. We're here to change that. 🔬 Protocol Intelligence | Site & PI Matching | Feasibility Automation | Custom Healthcare AI #ClinicalTrials #DrugDevelopment #HealthcareAI #ClinicalOperations #RealWorldEvidence #Pharma #Biotech #ClinicalResearch #AIinHealthcare #StudyStartup #DigitalHealth #PharmaTech
Verified activity
Signals from Research Lambda
10 published signals
Research & Knowledge
Research Lambda reported that the primary endpoint for the NCT07787338 trial is total pathological complete response (tpCR) assessed at surgery by an independent review committee.
Reported by Research Lambda
Research & Knowledge
Research Lambda reported that participants in the NCT07787338 trial first receive 4 cycles of SHR-A1811 monotherapy, followed by 4 additional cycles if tumor burden falls by 50% or more by RECIST 1.1 imaging criteria.
Reported by Research Lambda
Research & Knowledge
Research Lambda reported that if tumor reduction is less than 50%, treatment switches to THPy—docetaxel, trastuzumab, and pyrotinib for 4 cycles before surgery.
Reported by Research Lambda